Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
GlobeNewswire Inc.
1 hours ago
Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusion burden com
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
GlobeNewswire Inc.
2 hours ago
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- -- Positive re
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
GlobeNewswire Inc.
2 hours ago
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE
1win VIP Community Member Ilia Topuria Sets for Historic UFC Freedom 250 Main Event
Newsfile
9 hours ago
Mexico City, Mexico--(Newsfile Corp. - June 13, 2026) - As UFC lightweight champion Ilia Topuria prepares for one of the biggest fights of his career, international brand 1win highlights the recent acceptance of the undefeated MMA superstar to the 1w
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
12 hours ago
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
GlobeNewswire Inc.
12 hours ago
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have signific
NU E Power Corp. Files 2026 First Quarter Results
Newsfile
Yesterday at 11:22 PM GMT
Calgary, Alberta--(Newsfile Corp. - June 12, 2026) - NU E Power Corp. (CSE: NUE) ("NUE" or the "Company") announces that it has filed its unaudited interim condensed consolidated financial statements and management's discussion and analysis ("MD&A")
CleanTech Issues Clarification Regarding Qualified Person Disclosure
Newsfile
Yesterday at 10:12 PM GMT
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - CleanTech Vanadium Mining Corp. (TSXV: CTV) (OTCQB: CTVFF) ("CleanTech" or the "Company") wishes to clarify that the Qualified Person disclosure contained in its news release dated June
Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m
Newsfile
Yesterday at 9:40 PM GMT
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes from the recently concluded deep drilling campaign at
Joint News Release Smartset Services Inc. and FinCard Financial Services Inc. Announce Binding Letter of Intent for Qualifying Transaction
Newsfile
Yesterday at 9:36 PM GMT
Vancouver, British Columbia and Edmonton, Alberta--(Newsfile Corp. - June 12, 2026) - Smartset Services Inc. (TSXV: SMAR.P) ("Smartset" or the "Company") and FinCard Financial Services Inc. ("FinCard") are pleased to announce that they have entered i

